Related Experiment Video

Updated: Dec 8, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.0K

Recent progress in small molecule agents for the targeted therapy of triple-negative breast cancer

Rajibul Islam1, Kok Wai Lam1

  • 1Drugs and Herbal Research Centre, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300, Kuala Lumpur, Malaysia.

European Journal of Medicinal Chemistry
|September 16, 2020
PubMed

Insights

Triple-negative breast cancer (TNBC) is aggressive, lacking targeted treatments. This review covers small-molecule targeted therapies and discusses combining them with immunotherapy for better outcomes in TNBC patients.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Triple-negative breast cancer (TNBC) represents an aggressive subtype with limited therapeutic options.
  • Current treatments like surgery, chemotherapy, and radiotherapy for TNBC are associated with significant side effects.
  • There is a critical unmet need for effective and targeted treatment strategies for TNBC.

Purpose of the Study:

  • To review recent advancements in small-molecule targeted therapy for triple-negative breast cancer.
  • To explore the potential of combining targeted therapy with immunotherapy for enhanced TNBC treatment efficacy.

Main Methods:

  • Literature review of current research on small-molecule targeted agents for TNBC.
  • Analysis of preclinical and clinical data on targeted therapy and immunotherapy combinations.

Main Results:

  • Small-molecule targeted therapies are emerging as promising treatment options for TNBC.
  • Combination strategies involving targeted therapy and immunotherapy show potential for improved patient outcomes.

Conclusions:

  • Targeted therapy offers a new avenue for treating aggressive TNBC.
  • Combining targeted agents with immunotherapy may overcome treatment resistance and improve survival rates in TNBC.
Keywords:
Combination therapyImmunotherapySmall molecule agentTargeted therapyTriple-negative breast cancer

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.5K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K